Tolterodine to relieve urinary symptoms following transurethral resection of the prostate: A double-blind placebo-controlled randomized clinical trial

To evaluate the effect of tolterodine on early storage symptoms following transurethral
resection of the prostate.
Materials and Methods: Seventy patients over 55 years of age who underwent transurethral
resection of the prostate owing to benign prostatic hyperplasia were randomly
assigned to receive either 2 mg of tolterodine twice daily (treatment group) or matched
placebo during a 1-month study period. Before and 1 month after the procedure, they
were asked to complete the International Prostate Symptom Score (IPSS) questionnaire
and quality of life subscale to assess their symptoms. Also, analgesic use and
adverse drug events were determined at follow-up.
Results: Of 70 allocated patients, 64 patients (91.4%), including 33 in the treatment
group and 31 in the placebo group, completed the study. The mean age of the patients
was 67 years. None of the patients’ basic clinical characteristics were significantly
different. At the end of the follow-up period, the total IPSS and quality of life score had
significantly improved in the patients receiving tolterodine compared with those receiving
placebo (p=0.001 and p=0.036, respectively). The treatment group compared with
placebo demonstrated significant improvements in frequency and urgency but not in
nocturia. The amount of consumed painkiller was also significantly lower in the tolterodine
group than in the placebo group (p=0.0001). The rate of side effects was not significantly
different between the groups.
Conclusions: Administering 2 mg of tolterodine twice daily is an effective and well-tolerated
regimen to relieve early storage symptoms, quality of life, and the amount of
analgesic consumption following transurethral resection of the prostate